Literature DB >> 27768140

Informed Consent: A Clinical Trials Perspective

Marilyn J Hammer1, Patricia Eckardt2, Margaret Barton-Burke3.   

Abstract

The primary goal of the thousands of registered trials in cancer research is to extend survival. With evaluation of efficacy, safety, and tolerability, healthcare providers must ensure that the principles described in the Belmont Report are upheld and that patients are truly informed when signing a consent form. In this article, two cases are highlighted, and reasons for participating in clinical trials are discussed. Challenges, such as healthcare literacy, patients' dedication to their healthcare providers, and choosing between multiple trials, are also explored.

Entities:  

Keywords:  biology of cancer; ethics; genetics; nursing research

Mesh：

Year:  2016        PMID： 27768140      PMCID： PMC5637387          DOI： 10.1188/16.ONF.694-696

Source DB:  PubMed          Journal:  Oncol Nurs Forum        ISSN： 0190-535X            Impact factor:   2.172


  5 in total

1.  The death of Jesse Gelsinger: new evidence of the influence of money and prestige in human research.

Authors:  Robin Fretwell Wilson
Journal:  Am J Law Med       Date:  2010

2.  Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.

Authors:  David L Porter; Bruce L Levine; Michael Kalos; Adam Bagg; Carl H June
Journal:  N Engl J Med       Date:  2011-08-10       Impact factor: 91.245

Review 3.  Gene therapy: trials and tribulations.

Authors:  N Somia; I M Verma
Journal:  Nat Rev Genet       Date:  2000-11       Impact factor: 53.242

Review 4.  Challenges in translating endpoints from trials to observational cohort studies in oncology.

Authors:  Anne Gulbech Ording; Deirdre Cronin-Fenton; Vera Ehrenstein; Timothy L Lash; John Acquavella; Mikael Rørth; Henrik Toft Sørensen
Journal:  Clin Epidemiol       Date:  2016-06-11       Impact factor: 4.790

5.  Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program.

Authors:  Antoine Adenis; Christelle de la Fouchardiere; Bernard Paule; Pascal Burtin; David Tougeron; Jennifer Wallet; Louis-Marie Dourthe; Pierre-Luc Etienne; Laurent Mineur; Stéphanie Clisant; Jean-Marc Phelip; Andrew Kramar; Thierry Andre
Journal:  BMC Cancer       Date:  2016-07-07       Impact factor: 4.430
  5 in total
  2 in total

Review 1.  Gene-Based Therapeutics for Parkinson's Disease.

Authors:  Karim E Shalaby; Omar M A El-Agnaf
Journal:  Biomedicines       Date:  2022-07-26

Review 2.  CRISPR Gene Therapy: Applications, Limitations, and Implications for the Future.

Authors:  Fathema Uddin; Charles M Rudin; Triparna Sen
Journal:  Front Oncol       Date:  2020-08-07       Impact factor: 6.244
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.